Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Equity Average (2018 - 2025)

X4 Pharmaceuticals' Equity Average history spans 8 years, with the latest figure at $124.0 million for Q4 2025.

  • For Q4 2025, Equity Average rose 203.18% year-over-year to $124.0 million; the TTM value through Dec 2025 reached $124.0 million, up 203.18%, while the annual FY2025 figure was $104.2 million, 184.57% up from the prior year.
  • Equity Average reached $124.0 million in Q4 2025 per XFOR's latest filing, up from $32.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $124.0 million in Q4 2025 to a low of $13.5 million in Q2 2025.
  • Average Equity Average over 5 years is $58.7 million, with a median of $59.5 million recorded in 2023.
  • The largest YoY upside for Equity Average was 203.18% in 2025 against a maximum downside of 71.81% in 2025.
  • A 5-year view of Equity Average shows it stood at $66.5 million in 2021, then rose by 2.11% to $68.0 million in 2022, then fell by 12.66% to $59.3 million in 2023, then tumbled by 31.11% to $40.9 million in 2024, then soared by 203.18% to $124.0 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Equity Average are $124.0 million (Q4 2025), $32.8 million (Q3 2025), and $13.5 million (Q2 2025).